Vimarsana
Biggest News Aggregation in the World

Page 4 - Programmed Cell Death News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Programmed Cell Death. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Programmed Cell Death Today - Breaking & Trending Today

The potential of targeting mitochondria-associated programmed cell death for age-related disease treatment - Vimarsana News

The potential of targeting mitochondria-associated programmed cell death for age-related disease treatment

The review summarized the involvement of mitochondria in age-related disease progression and highlighted its potential as a therapeutic target of these diseases.

How conversion between different types of cell death contributes to disease - Vimarsana News

How conversion between different types of cell death contributes to disease

Researchers elucidate the role of cell death in the pathogenesis of different diseases.

Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial - Vimarsana News

Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial

/PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

Nutrition meets cancer therapy: How gut microbiome and diet impact immunotherapy success - Vimarsana News

Nutrition meets cancer therapy: How gut microbiome and diet impact immunotherapy success

Researchers investigated the complex relationship between gut bacteria, diet, and patient nutrition.

Phase 1 clinical trial underway to test City of Hope-developed cancer treatment - Vimarsana News

Phase 1 clinical trial underway to test City of Hope-developed cancer treatment

Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, today published a new study explaining how they took a protein once thought to be too challenging for targeted therapy, proliferating cell nuclear antigen (PCNA), and developed a targeted chemotherapy that appears to annihilate all solid tumors in preclinical research.